Evidence map›Paper›PMID 36894729›Full record

ArticleMikrochimica acta2023

A SERS/fluorescence dual-mode immuno-nanoprobe for investigating two anti-diabetic drugs on EGFR expressions.

Yuqi Cheng, Lili Cong, Xiaozhang Qu, Junyi Zhao, Jiamin Chen, Ping Li, Wei Shi, Weiqing Xu, Shuping Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuqi ChengState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, People's Republic of China.
Lili CongState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, People's Republic of China.
Xiaozhang QuThe First Hospital of Jilin University, Changchun, 130031, People's Republic of China.
Junyi ZhaoState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, People's Republic of China.
Jiamin ChenState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, People's Republic of China.
Ping LiRheumatology and Immunology Department, China-Japan Union Hospital of Jilin University, Changchun, 130033, People's Republic of China. li_ping@jlu.edu.cn.
Wei ShiKey Lab for Molecular Enzymology & Engineering of Ministry of Education, Jilin University, Changchun, 130012, People's Republic of China.
Weiqing XuState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, People's Republic of China.
Shuping XuState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, People's Republic of China. xusp@jlu.edu.cn.ORCID http://orcid.org/0000-0002-6216-6175
Jilin University · CN

Funding

Department of Finance of Jilin Province 2021CSZ14Interdisciplinary Integration Innovation Project of Jilin University JLUXKJC2020106National Natural Science Foundation of China 21827805National Natural Science Foundation of China 21873039National Natural Science Foundation of China 22173035Technology Development Program of Jilin Province 20220101046JCthe opening project of State Key Laboratory of Applied Optics SKLAO2021001A14
6 · The paper itself

Abstract

A surface-enhanced Raman scattering (SERS)/fluorescence dual-mode nanoprobe was proposed to assess anti-diabetic drug actions from the expression level of the epidermal growth factor receptor (EGFR), which is a significant biomarker of breast cancers. The nanoprobe has a raspberry shape, prepared by coating a dye-doped silica nanosphere with a mass of SERS tags, which gives high gains in fluorescence imaging and SERS measurement. The in situ detection of EGFR on the cell membrane surfaces after drug actions was achieved by using this nanoprobe, and the detection results agree with the enzyme-linked immunosorbent assay (ELISA) kit. Our study suggests that rosiglitazone hydrochloride (RH) may be a potential drug for diabetic patients with breast cancer, while the anti-cancer effect of metformin hydrochloride (MH) is debatable since MH slightly promotes the EGFR expression of MCF-7 cells in this study. This sensing platform endows more feasibility for highly sensitive and accurate feedback of pesticide effects at the membrane protein level.

Indexed as

Breast NeoplasmsEnzyme-Linked Immunosorbent AssayErbB ReceptorsFemaleFluorescenceHumansOptical ImagingEGFR protein, humanErbB ReceptorsDrug actionDual-mode probeEGFR expressionFluorescence imagingIn situ analysisMembrane receptors

Identifiers

PMID36894729
OpenAlexW4323809331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.